Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models

BACKGROUND: Interleukin-12 (IL-12) is a potent, proinflammatory cytokine that holds promise for cancer immunotherapy, but its clinical use has been limited by its toxicity. To minimize systemic exposure and potential toxicity while maintaining the beneficial effects of IL-12, we developed a novel IL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ling, Davies, John S, Serna, Carylinda, Yu, Zhiya, Restifo, Nicholas P, Rosenberg, Steven A, Morgan, Richard A, Hinrichs, Christian S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057422/
https://www.ncbi.nlm.nih.gov/pubmed/31959727
http://dx.doi.org/10.1136/jitc-2019-000210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057422/
https://www.ncbi.nlm.nih.gov/pubmed/31959727
http://dx.doi.org/10.1136/jitc-2019-000210

Ejemplares similares